RS60646B1 - Natrijumova so n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida - Google Patents

Natrijumova so n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida

Info

Publication number
RS60646B1
RS60646B1 RS20200936A RSP20200936A RS60646B1 RS 60646 B1 RS60646 B1 RS 60646B1 RS 20200936 A RS20200936 A RS 20200936A RS P20200936 A RSP20200936 A RS P20200936A RS 60646 B1 RS60646 B1 RS 60646B1
Authority
RS
Serbia
Prior art keywords
indacen
hexahydro
sulfonamide
pyrazole
carbamoyl
Prior art date
Application number
RS20200936A
Other languages
English (en)
Inventor
David Miller
Angus Macleod
Rio Gancedo Susana Del
Samuel Alexander Stratford
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of RS60646B1 publication Critical patent/RS60646B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20200936A 2018-04-23 2019-04-23 Natrijumova so n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida RS60646B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1806578.9A GB201806578D0 (en) 2018-04-23 2018-04-23 Novel compound
PCT/EP2019/060311 WO2019206871A1 (en) 2018-04-23 2019-04-23 A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
EP19721230.1A EP3606909B1 (en) 2018-04-23 2019-04-23 A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide

Publications (1)

Publication Number Publication Date
RS60646B1 true RS60646B1 (sr) 2020-09-30

Family

ID=62236309

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200936A RS60646B1 (sr) 2018-04-23 2019-04-23 Natrijumova so n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida

Country Status (27)

Country Link
US (2) US10973803B2 (sr)
EP (2) EP3722281A1 (sr)
JP (1) JP7382958B2 (sr)
KR (1) KR20210005589A (sr)
CN (1) CN112020495B (sr)
AR (1) AR114827A1 (sr)
AU (1) AU2019257973A1 (sr)
BR (1) BR112020021650A2 (sr)
CA (1) CA3097832A1 (sr)
CY (1) CY1123260T1 (sr)
DK (1) DK3606909T3 (sr)
ES (1) ES2811228T3 (sr)
GB (1) GB201806578D0 (sr)
HR (1) HRP20201263T1 (sr)
HU (1) HUE050369T2 (sr)
LT (1) LT3606909T (sr)
MA (2) MA51082A (sr)
MD (1) MD3606909T2 (sr)
ME (1) ME03822B (sr)
MX (1) MX2020011196A (sr)
PL (1) PL3606909T3 (sr)
PT (1) PT3606909T (sr)
RS (1) RS60646B1 (sr)
SI (1) SI3606909T1 (sr)
TW (1) TW201943704A (sr)
UY (1) UY38186A (sr)
WO (1) WO2019206871A1 (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55695A (fr) 2017-01-23 2022-02-23 Genentech Inc Composés chimiques comme inhibiteurs de l'activité interleukine-1
JP7072586B2 (ja) 2017-05-24 2022-05-20 ザ ユニバーシティ オブ クィーンズランド 新規な化合物及び使用
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
WO2019034692A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
BR112020003014A2 (pt) 2017-08-15 2020-07-28 Inflazome Limited sulfonilureias e sulfoniltioureias como inibidores de vnlrp3
US11518739B2 (en) 2017-08-15 2022-12-06 Inflazome Limited Sulfonamide carboxamide compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP7411631B2 (ja) 2018-07-20 2024-01-11 エフ. ホフマン-ラ ロシュ アーゲー インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
EP4076441A2 (en) * 2019-11-07 2022-10-26 Inflazome Limited Treatment and prevention of a neurodegenerative disorder
GB201916237D0 (en) * 2019-11-07 2019-12-25 Inflazome Ltd Novel treatment
CN114630664A (zh) * 2019-11-07 2022-06-14 英夫拉索姆有限公司 神经炎症或炎性脑部病症的治疗和预防
WO2021089781A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide
CN114599356A (zh) * 2019-11-07 2022-06-07 英夫拉索姆有限公司 自身炎症性病症的治疗
WO2021089776A1 (en) * 2019-11-07 2021-05-14 Inflazome Limited Treatment and prevention of a traumatic brain disorder
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
AU6464400A (en) * 1999-09-14 2001-04-17 Pfizer Products Inc. Combination treatment with il-1ra and diaryl sulphonyl urea compounds
EP2781216A4 (en) * 2011-09-02 2015-05-27 Kyowa Hakko Kirin Co Ltd CHEMOKINREZEPTORAKTIVITÄTSREGLER
ES2881228T3 (es) 2015-02-16 2021-11-29 Univ Queensland Sulfonilureas y compuestos relacionados y uso de los mismos
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
KR20180133244A (ko) 2016-02-16 2018-12-13 더 유니버서티 어브 퀸슬랜드 설포닐유레아 및 관련 화합물 및 이의 용도
US11597706B2 (en) 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7041668B2 (ja) 2016-04-18 2022-03-24 ノバルティス アーゲー Nlrp活性に関連する状態を処置するための化合物および組成物
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes

Also Published As

Publication number Publication date
MA48051B1 (fr) 2020-08-31
EP3606909B1 (en) 2020-05-27
CA3097832A1 (en) 2019-10-31
LT3606909T (lt) 2020-10-12
MD3606909T2 (ro) 2020-08-31
US20210315862A1 (en) 2021-10-14
AR114827A1 (es) 2020-10-21
HRP20201263T1 (hr) 2021-02-05
KR20210005589A (ko) 2021-01-14
AU2019257973A1 (en) 2020-11-19
CN112020495A (zh) 2020-12-01
MX2020011196A (es) 2020-11-13
EP3722281A1 (en) 2020-10-14
SI3606909T1 (sl) 2020-09-30
CN112020495B (zh) 2024-05-17
BR112020021650A2 (pt) 2021-01-26
GB201806578D0 (en) 2018-06-06
CY1123260T1 (el) 2021-12-31
WO2019206871A1 (en) 2019-10-31
TW201943704A (zh) 2019-11-16
ME03822B (me) 2021-04-20
EP3606909A1 (en) 2020-02-12
HUE050369T2 (hu) 2020-11-30
MA51082A (fr) 2021-05-19
DK3606909T3 (da) 2020-08-24
US20200237723A1 (en) 2020-07-30
PT3606909T (pt) 2020-07-09
UY38186A (es) 2019-11-29
ES2811228T3 (es) 2021-03-11
PL3606909T3 (pl) 2020-11-16
US10973803B2 (en) 2021-04-13
JP7382958B2 (ja) 2023-11-17
JP2021522195A (ja) 2021-08-30

Similar Documents

Publication Publication Date Title
HUE050369T2 (hu) N - ((1,2,3,5,6,7-hexahidro-S-indacen-4-il) -karbamoil)-1-izopropil-1H-pirazol-3-szulfonamid nátrium-sója
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
IL279801A (en) Active pesticidal azole-amide compounds
IL275763A (en) Benzamide compounds
EP3867237C0 (en) PESTICIDAL AZOLE AMIDE COMPOUNDS
MX2020009947A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
IL286871A (en) Diazine-amide compounds are active as pesticides
IL286564A (en) Diazine-amide compounds are active as pesticides
IL286422A (en) Diazine-amide compounds are active as pesticides
EP3935053C0 (en) PESTICIDAL AZOLE AMIDE DERIVATIVES
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
IL290692A (en) Salt
EP3865473A4 (en) QUATERNARY TRIPHENYL-PHOSPHONIUM SALT COMPOUND, METHOD FOR PREPARATION AND APPLICATION
IL288575A (en) N-(pyrid-3-yl)carboxamides fungicides
IL276196A (en) Synthesis of 5-chloro-2-[(3,4,4-trifluoro-3-buten-1-yl)thio]-thiazole
WO2017191619A3 (en) A process for the preparation of a salt of sacubitril and valsartan
GB201919212D0 (en) Dihydro-cyclopenta-isoquinoline sulfonamides derivatives
EP3875449A4 (en) 1,4-DIAZOCANE COMPOUND OR SALT THEREOF
MY174415A (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
HK1256253A1 (zh) 化合物n-(3,5-二甲基苯基)-n'-(2-三氟甲基苯基)胍的製備方法
GB201904190D0 (en) Salt
GB201906171D0 (en) Di-peptides
GB201919216D0 (en) Tetrahydrobenzo-quinoline sulfonamides derivative compounds
NO2018026I2 (no) Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir
EP3875463A4 (en) CYCLIC DI-AMP SODIUM SALT CRYSTAL